Background. Hidradenitis suppurativa (HS) is a chronic debilitating cutaneous inflammatory condition caused by follicular occlusion/rupture with resultant inflammatory response. No durable control of HS is seen with current management strategies including topical and/or oral antibiotics, immunomodulatory drugs and local surgery. A recent French study using IV ertapenem for ≥4 weeks showed significant control of severe HS in patients (patients) who failed alternate medical strategies. We performed a prospective trial to study the effectiveness of IV ertapenem in severe HS.
Methods. A prospective pilot clinical study was done at Henry Ford Hospital, Detroit from May 2013 to December 2015. All patients with severe HS (Hurley Stage III) and who failed medical management by Dermatology were referred to Infectious Diseases for daily IV ertapenem through a PICC line. Patients were followed up for at least 6 months after completion of therapy with weekly monitoring. Data including demographics, clinical response/adverse effects to ertapenem and any PICC line-related complications were recorded. Response to the treatment was based on clinical improvement in pain score/drainage and Hurley Staging of HS.
Results. Twenty-three patients with severe HS consented to participate with a median age of 40 years (range 23-78 years) and 56% were female. Median treatment duration was 8 weeks (range 6-12). A 100% response rate was observed within 2 weeks of initiation and near complete resolution of active inflammation/drainage and improvement of pain score was observed in all patients at the end of treatment. Durable response was variable after completion of ertapenem (median 4 weeks; range 2-12); all subjects relapsed with varying degree of severity. In three patients who relapsed back to Hurley Stage III, ertapenem was restarted after 3 months with successful response. Adverse events include diarrhea (four patients), Clostridium difficile infection (one patient), and PICC line-related DVT (three patients). Clinical benefit despite ertapenem non-responsive bacteria in pretreatment culture of cutaneous drainage suggests an unproven immune-modulatory activity. Role of gut/skin microbial alteration needs further study.
Conclusion. In selected patients with severe HS, IV ertapenem is highly effective in the control of inflammation and can be useful in combination with local surgery.
Disclosures. Methods. Adults admitted to Detroit Medical Center from 1/2012 to 12/2015 with culture-positive DFI were included. Associations between outcomes and MDRO-DFI (evaluated as a single group that included methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci, Enterobacteriaceae-resistant to third-generation cephalosporins and/or carbapenems (Enterobacteriacae-R), Acinetobacter baumannii, and Pseudomonas aeruginosa) were analyzed. Outcomes included above and below knee lower extremity amputation (LEA) and readmissions and mortality within a year following DFI. A propensity score predicting the likelihood of having MDRO-DFI was computed by comparing patients with MDRO-DFI to patients with DFI not due to MDROs (non-MDRO-DFI). A conditional logistic model was constructed for each outcome, and MDRO-DFI was analyzed as an independent variable after patients in the MDRO and non-MDRO groups were matched by propensity score.
Results. 674 patients were included, with a mean age of 58.6 ± 13.8. Sixtyfour percent were male and 73% African American. Median Charlson score was 7 (IQR 5-9). Most patients (n = 394, 59%) had MDRO-DFI and MRSA was the most common (235, 60% of MDRO-DFI patients), followed by P. aeruginosa (25%) and Enterobacteriaceae-R (15%). In bivariate analyses LEA and 1 year readmission were more common in the MDRO-DFI group (Table) . However, in propensity-adjusted analyses, MDRO-DFI was no longer associated with LEA or hospital readmission.
Conclusion. LEA occurred in > 20% of DFI-MDRO patients, and >60% of patients were readmitted to the hospital within a year following a DFI-MDRO episode. In propensity-adjusted analyses, DFI-MDRO was not significantly associated with these clinical outcomes. Table: Impact of DFI-MDRO on outcomes 
Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Michael J. Rybak, PharmD, MPH, PhD 1 ; Evan J. Zasowski, PharmD, BCPS 1 ; Trangan ABSSSI diagnosis presenting to two academic medical centers in Detroit, MI from 2010 to 2015 were included. Baseline/clinical characteristics and outcomes were compared between cases (ABSSSI + BSI) and controls (ABSSSI). Outcomes included in-hospital mortality, hospital length of stay (los) and 30-day reinfection. Fisher's exact and Student's t-or Mann-Whitney U-tests were used for bivariate comparisons. Variables associated with ABSSSI + BSI in bivariate analysis at a P-value < 0.1 were included in multivariable logistic regression to examine factors independently associated with ABSSSI + BSI.
Results. 392 patients consisting of 196 ABSSSI + BSI and 196 controls ABSSSI were evaluated. In bivariate analysis, individuals with ABSSSI + BSI were significantly older (P < 0.001), more likely to be male (P = 0.008), be an intravenous drug user (P = 0.012), have chronic renal failure (P = 0.002), prior hospitalization (P <0.001), and more systemic symptoms, such as elevated temperature, white blood cell count, and acute renal failure on hospital admission (P < 0.001). By regression, male gender (aOR 1.85, 95% CI 11-3.66), acute renal failure (aOR 2.08, 95% CI 1.18-3.67), intravenous drug use (aOR 4.38, 95% CI 2.22-8.62), and prior hospitalization (aOR 2.41, 95% CI 1.24-4.93) remained statistically significant. ABSSSI + BSI patients were more likely to experience in-hospital mortality (4.1 vs. 0%, P <0.001), have longer mean loss (7.4 ± 5.7 vs. 2.7 ± 2.2 days, P = <0.001), and experience 30-day reinfection (11.2 vs. 4.1%, P = 0.006).
Conclusion. Patients with ABSSSI + BSI had worse outcomes than those with ABSSSI alone. Factors associated with ABSSSI + BSI, such as gender, IVDU, prior hospitalization, renal failure, and systemic signs/symptoms of infection, may be used to identify patients at risk for ABSSSI + BSI.
Disclosures. Background. There are limited published data regarding the post-discharge treatment epidemiology for most infections, including acute bacterial skin and skin structure infections (ABSSSIs).
Methods. This is a national descriptive study of Veterans Affairs medical center admissions with diagnosis codes for ABSSSIs between January 1, 2005 and September 30, 2015. Patients receiving vancomycin during this admission were selected for inclusion. Treatment approaches after hospital discharge, including oral antibiotics, as well as intravenous (IV) medications administered in an outpatient clinic were assessed. Differences between oral and IV groups were assessed with χ 2 or Wilcoxon tests as appropriate.
Results. Of the 118,135 ABSSSI admissions, 114,352 (96.8%) patients continued antibiotic therapy after discharge. Most patients (98.5%) continued on oral therapy (median length of stay 4 days vs 6 days in IV group; P < 0.05). The most common oral therapies after discharge were sulfamethoxazole/trimethoprim (n = 30,220, 26.8%) and amoxicillin clavulanate (n = 21,819, 19.4%). The most common IV antibiotics were vancomycin (n = 740, 57.5%) and ceftriaxone (n = 220, 17.1%). Significant differences in demographics and comorbidities were observed between the oral and IV groups; however, absolute differences were negligible in some cases (e.g., median age 61 in oral group and 62 in IV group). Cultures were taken in less than half of patients (37.9% oral, 49.7% IV; P < 0.05), of which most were Staphylococcus aureus (81.7% oral, 78.4% IV; P < 0.05), with higher methicillin resistance in the IV group (59.1% oral, 63.7% IV; P < 0.05). In unadjusted comparisons between the oral and IV groups, the following 30-day outcomes differed significantly (P < 0.05): emergency room visit (21.6% oral, 45.3% IV), readmission (13.8% oral, 25.5% IV), and reinfection (45.7% oral, 54.3% IV).
Conclusion. Most patients with ABSSSI admissions continued antibiotic therapy after discharge, with only 1.1% receiving IV antibiotics in an outpatient clinic after discharge. Demographic characteristics and comorbidity burden were similar between the oral and IV groups; however, small absolute differences were statistically significant as this was a large cohort. Background. Acute bacterial skin and skin structure infections (ABSSSI) are a challenging medical problem associated with high health care costs. Dalbavancin and oritavancin are approved for treatment of ABSSSI and, due to their long half-life, are dosed as a one-time infusion. These agents may make it possible to allow for earlier discharge and reduce health care costs without compromising efficacy.
Methods. Retrospective chart review was performed for patients discharged from Abbott Northwestern Hospital (ANW) with primary diagnosis of skin and soft-tissue infection between October 1, 2015 and September 30, 2016. Inclusion and exclusion criteria were approved by ANW Antimicrobial Stewardship Committee and used to retrospectively identify potential candidates for oritavancin or dalbavancin. Retrospective cost-analysis was performed to assess potential cost savings with the use of dalbavancin or oritavancin instead of the traditional antibiotic therapy that was used. Financial impact was assessed taking into consideration potential cost savings and additional expenses with the use of dalbavancin or oritavancin. Data are presented as mean ± standard deviation. Statistical comparison between actual and predicted length of hospital stay was performed using paired t-test. P < 0.05 was considered statistically significant.
Results. In total, 294 admissions were identified. Eight patients met the selection criteria with the majority being intravenous drug users. Actual length of stay of candidates for dalbavancin or oritavancin was 4.3 ± 2.8 days. Predicted length of hospital stay if dalbavancin or oritavancin were used was 3.0 ± 1.9 days (P = 0.03 vs. actual length of stay). The use of dalbavancin or oritavancin may have prevented four readmissions, two peripherally inserted central catheter insertions, and the use of daptomycin in one patient. Despite the potential cost savings, the use of dalbavancin or oritavancin would result in an additional cost to ANW by an estimate of $937 to $20,107 a year.
Conclusion. Dalbavancin or oritavancin may have been used in a small proportion of admissions (3%) with skin and soft-tissue infection as primary diagnosis. The high cost of dalbavancin and oritavancin offset any potential cost savings resulting in additional costs to ANW estimated to be up to $20,000 a year.
Disclosures. Background. Fournier's gangrene is an uncommon but often devastating infection. There are few contemporary data on the risk factors and evolving microbiologic trends including drug-resistant organisms implicated in these life-threatening infections.
Methods. A retrospective study of Fournier's gangrene from 2006 to 2015 at a large academic hospital was conducted. Cases were identified using ICD codes (ICD-9: 608.83, V13.89; ICD-10: N49.3, Z87.438), and a review of medical and pathology records was performed to confirm each case. Data collected included socio-demographics, medical conditions, bacterial pathogens and their resistance patterns, treatments, and outcome. Descriptive and univariate statistics were performed.
Results. In total, 59 cases were evaluated with an incidence of 31.8 cases per 100,000 admissions over the study period. Mean age was 56 years (range 18-91), 71% were male, and 45% white. Diabetes was noted among 26 (44%) with a mean A1c of 9.6%. Other risk factors included: overweight/obesity (61%), immunocompromised state (34%), and substance use (32%). A causative organism was identified in all but two cases; 12 patients (21%) had an MDRO with MRSA being the most common pathogen (n = 8, 14% of all cases), followed by ESBL E. coli (n = 3) and MDRO Acinetobacter (n = 1). MRSA was the sole pathogen in five (63%) of the eight cases involving this organism. Among those with an aerobic Gram-negative rod (GNR) isolated, 31% were fluoroquinolone-resistant. An MDRO infection was significantly associated with an immunocompromised state (OR 5.5, P = 0.01) and chronic wounds (OR 7.0, P = 0.02). Overall, 30% of all cases had an adverse outcome (15% died and an additional 15% had loss of an organ). Those with MDRO were more likely to experience an adverse outcome (42% vs. 28%), although this was not statistically significant (P = 0.48); of note most (83%) MDRO cases were treated with an initial antibiotic with efficacy against the MDRO.
Conclusion. This report suggests a much higher incidence of Fournier's gangrene than previously described and highlights the emergence of MDROs as an important cause of these infections including MRSA and drug-resistant GNRs. Antibiotics should be chosen with broad-spectrum, anti-MDRO activity given the high morbidity and mortality associated with these infections.
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